Marcio de Paula
Sep 27, 2024
Non-refundable financial subsidy for companies operating in research, development and innovation in the health sector
The Ministry of Science, Technology and Innovation (MCTI) and the Study and Project Financing Agency - FINEP make public this Selection, the objective of which is to grant economic subsidy resources for innovative and technologically risky projects, which meet the purposes defined in this regulation and its annexes.
Research, development and innovation to reduce the vulnerabilities of the SUS and contribute to expanding the population's access to healthcare. Available amount: R$250 million (economic subsidy – non-reimbursable for companies).
Support for projects in the following thematic lines:
Active Pharmaceutical Ingredients: Innovative APIs (green, chemical or biological) or improvement of existing APIs;
Biological products with high impact for the SUS : new monoclonal antibodies for the country or biosimilars without local production, development of blood-derived medicines;
Clinical Research for innovation in the country: carrying out clinical trials in the network of Brazilian university hospitals, covering only phase 1 and/or phase 2;
Priority Products: new alternatives in prevention, diagnosis and treatment within the scope of SUS priorities for the Partnerships Program for Productive Development, the Local Development and Innovation Program and other strategic Programs related to S,T&I established by the Ministry of Health, including Neglected and/or Socially Determined Tropical Diseases.
Access information about the notice .